An epidemic of parvovirus B19 in a population of 3596 pregnant women: A study of sociodemographic and medical risk factors

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 107, Issue 5, 2000, Pages 637-643

  Jensen, Inge Panum ^a   Thorsen, Poul ^b   Jeune, Bernard ^c   Møller, Birger R ^d   Vestergaard, Bent F ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF AARHUS   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; ARTICLE; BLOOD SAMPLING; DEMOGRAPHY; DENMARK; EPIDEMIC; ERYTHEMA INFECTIOSUM; FEMALE; HUMAN; NORMAL HUMAN; PARVOVIRUS; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL PERIOD; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SEROCONVERSION; SEROLOGY; SOCIAL CLASS; SPONTANEOUS ABORTION; STILLBIRTH; WORK;

ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; FEMALE; FETAL DEATH; HUMANS; INCIDENCE; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0034053262     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2000.tb13306.x     Document Type: Article

References (29)

1. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1: 72–73.
2. Kerr JR. Parvovirus B19 infection. Eur J Clin Microbiol Infect Dis 1996; 15: 10–29.
3. Knott PD, Welply GA, Anderson MJ. Serologically proved intrauterine infection with parvovirus. BMJ 1984; 289: 1660.
4. Public Health Laboratory Service Working Party on Fifth Disease. Prospective study of human parvovirus (B19) infection in pregnancy. BMJ 1990; 300: 1166–1170.
5. Leads from the MMWR. Risks associated with human parvovirus B19 infection. JAMA 1989; 261: 1406–1408.
6. Panum Jensen I, Faber Vestergaard B. Assessment of the specificity of a commercial human parvovirus B19 IgM assay. Clin Diagn Virol 1997; 7: 133–137.
7. Enevoldsen B, Michelsen N. Social classification. Svalastoga's subdivision according to social status rank a the social grouping employed by the Institute for Social Research. Ugeskr Laeger 1980; 142: 544–550.
8. Hosmer DW, Lemeshow S. Model-Building Strategies and Methods for Logistic Regression. In: Applied Logistic Regression. New York: John Wiley, 1989: 82–134.
9. Jensen IP, Schou O, Vestergaard BF. The 1994 human parvovirus B19 epidemic in Denmark: Diagnostic and epidemiological experience. APMIS 1998; 106: 843–848.
10. Enders G, Biber M. Parvovirus B19 infections in pregnancy. Behring Inst Mitt 1990; 85: 74–78.
11. Gratacós E, Torres PJ, Vidal J et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis 1995; 171: 1360–1363.
12. Yaegashi N, Niinuma T, Chisaka H et al. Serologic study human parvovirus B19 infection in pregnancy in Japan. J Infect Dis 1999; 38: 30–35.
13. Skjöldebrand-Sparre L, Fridell E, Nyman M, Wahren B. A prospective study of antibodies against parvovirus B19 in pregnancy. Acta Obstet Gynecol Scand 1996; 75: 336–339.
14. Kinney JS, Anderson LJ, Farrar J et al. Risk of adverse outcome of pregnancy after human parvovirus B19 infection. J Infect Dis 1988; 157: 663–667.
15. Gay NJ, Hesketh LM, Cohen BJ et al. Age specific antibody prevalence to parvovirus B19: how many women are infected in pregnancy Commun Dis Rep CDR Rev 1994; 4: R104–R107.
16. Cartter ML, Farley TA, Rosengren S et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis 1991; 163: 282–285.
17. Valeur-Jensen AK, Pedersen CB, Westergaard T et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA 1999; 281: 1099–1105.
18. Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998; 105: 174–178.
19. Harger JH, Adler SP, Koch WC, Harger GF. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol 1998; 91: 413–421.
20. Smoleniec JS, Pillai M, Caul EO, Usher J. Subclinical transplacental parvovirus B19 infection: an increased fetal risk Lancet 1994; 343: 1100–1101.
21. Adler SP, Manganello AMA, Koch WC, Hempfling SH, Best AIM. Risk of human parvovirus B19 infections among school and hospital employees during endemic periods. J Infect Dis 1993; 168: 361–368.
22. Chorba T, Coccia P, Holman RC et al. The role of parvovirus B19 in aplastic crisis and erythema infectionsum (fifth disease). J Infect Dis 1986; 154: 383–393.
23. Sheikh AU, Ernest JM. Clinical picture and consequences of fetal parvovirus B19 infection. Ann Med 1995; 27: 7–8.
24. Fairley CK, Smoleniec JS, Caul OE, Miller E. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995; 346: 1335–1337.
25. Schwarz TF, Roggendorf M, Hottenträger B et al. Human parvovirus B19 infection in pregnancy. Lancet 1988; 2: 566–567.
26. Pattison JR. Human parvovirus B19. BMJ 1994; 308: 149–150.
27. Cohen B. Parvovirus B19: an expanding spectrum of disease. BMJ 1995; 311: 1549–1552.
28. Smoleniec JS, Pillai M. Management of fetal hydrops associated with parvovirus B19 infection. Br J Obstet Gynaecol 1994; 101: 1079–1081.
29. Bansal GP, Hatfield JA, Dunn FE et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 1993; 167: 1034–1044.